Pardes Biosciences Stock Price To Earning
PRDSDelisted Stock | USD 2.14 0.01 0.47% |
Pardes Biosciences fundamentals help investors to digest information that contributes to Pardes Biosciences' financial success or failures. It also enables traders to predict the movement of Pardes Stock. The fundamental analysis module provides a way to measure Pardes Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pardes Biosciences stock.
Pardes |
Pardes Biosciences Company Price To Earning Analysis
Pardes Biosciences' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Pardes Biosciences has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.
Pardes Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pardes Biosciences' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pardes Biosciences could also be used in its relative valuation, which is a method of valuing Pardes Biosciences by comparing valuation metrics of similar companies.Pardes Biosciences is currently under evaluation in price to earning category among its peers.
Pardes Fundamentals
Return On Equity | -0.4 | |||
Return On Asset | -0.26 | |||
Current Valuation | (22.1 M) | |||
Shares Outstanding | 62.01 M | |||
Shares Owned By Insiders | 13.47 % | |||
Shares Owned By Institutions | 72.05 % | |||
Number Of Shares Shorted | 874.35 K | |||
Price To Book | 0.37 X | |||
EBITDA | (99.82 M) | |||
Net Income | (96.63 M) | |||
Cash And Equivalents | 228.6 M | |||
Cash Per Share | 3.67 X | |||
Current Ratio | 20.84 X | |||
Book Value Per Share | 2.57 X | |||
Cash Flow From Operations | (71.98 M) | |||
Short Ratio | 1.09 X | |||
Earnings Per Share | (1.28) X | |||
Target Price | 1.25 | |||
Number Of Employees | 57 | |||
Beta | 0.42 | |||
Market Capitalization | 133.95 M | |||
Total Asset | 200.62 M | |||
Retained Earnings | (148.16 M) | |||
Working Capital | 179.98 M | |||
Z Score | -1.6 | |||
Net Asset | 200.62 M |
About Pardes Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pardes Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pardes Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pardes Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Pardes Stock
If you are still planning to invest in Pardes Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pardes Biosciences' history and understand the potential risks before investing.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Fundamental Analysis View fundamental data based on most recent published financial statements |